The Davila Lab aims to understand the cellular and molecular signals that promote the generation of potent and long-lasting tumor-specific T cell responses. Early preclinical studies demonstrated that formulating vaccines to include toll like receptor agonists together with peptides representing tumor antigens induced potent CD8 cytotoxic T cell responses and were effective at treating tumors in a prophylactic and therapeutic setting. We continue to exploit the T cell’s ability to recognize and destroy tumors.
Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Davila E. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res. 2015 Mar 20;PubMed PMID: 25795705.
Kaczanowska S, Joseph AM, Guo J, Tsai AK, Lasola JJ, Younger K, Zhang Y, Gonzales CV, Davila E. A Synthetic CD8α:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. Cancer Res. 2017 Dec 15;77(24):7049-7058.
Jitao Guo, Elena Muse, Allison J. Christians, Steven J. Swanson, and Eduardo Davila. Using an anticancer drug cocktail of MK2206, Nut7441, and tramatenib to improve dendritic cell-based cancer vaccines. Cancer Immunol Res. Accepted May 2019